Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: Who is going to blink at the cost?

Ronan J. Kelly, Thomas J. Smith, Bruce E. Hillner

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Pages (from-to)983-985
Number of pages3
JournalJournal of Clinical Oncology
Issue number10
StatePublished - Apr 1 2014

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this